Document is current
Any future updates will be listed below
-
Authors
Ren, Feng
Aliper, Alex
Chen, Jian
Zhao, Heng
Rao, Sujata
Kuppe, Christoph http://orcid.org/0000-0003-4597-9833
Ozerov, Ivan V.
Zhang, Man
Witte, Klaus
Kruse, Chris
Aladinskiy, Vladimir
Ivanenkov, Yan
Polykovskiy, Daniil http://orcid.org/0000-0002-0899-8368
Fu, Yanyun
Babin, Eugene
Qiao, Junwen
Liang, Xing
Mou, Zhenzhen
Wang, Hui
Pun, Frank W.
Torres-Ayuso, Pedro http://orcid.org/0000-0003-2213-9014
Veviorskiy, Alexander
Song, Dandan
Liu, Sang
Zhang, Bei
Naumov, Vladimir
Ding, Xiaoqiang
Kukharenko, Andrey
Izumchenko, Evgeny
Zhavoronkov, Alex http://orcid.org/0000-0001-7067-8966
- License Information
-
More Information
Article History
Received: 26 June 2023
Accepted: 16 January 2024
First Online: 8 March 2024
Competing interests
: For A.Z. and listed authors that are affiliated with Insilico Medicine: Insilico Medicine is a global clinical-stage commercial generative AI company with several hundred patents and patent applications and commercially available software. Insilico Medicine is a company developing an AI-based end-to-end integrated pipeline for drug discovery and development that is engaged in drug-discovery programs for aging, fibrosis and oncology. F.R., A.A., H.Z., S.R., I.V.O., M.Z., K.W., C. Kruse, V.A., Y.I., D.P., Y.F., E.B., J.Q., X.L., Z.M., H.W., F.W.P., A.V., S.L., B.Z., V.N., A.K. and A.Z. are affiliated with Insilico Medicine or were affiliated with Insilico Medicine when the studies were performed. No other conflicts are reported.
